Allopurinol: Pharmacokinetics and Metabolism
Allopurinol (Allopurinolum) remains a foundational uric acid-lowering drug for reducing serum uric acid levels. When taken orally after meals, it exhibits high bioavailability ranging widely from 50 to 90%, meaning a significant portion of the ingested dose successfully reaches systemic circulation.
Upon entering the body, the drug undergoes extensive biotransformation. In liver tissues, allopurinol is converted into its primary active metabolite, oxypurinol. This metabolite plays a crucial role in the clinical efficacy of the entire therapy.
The pharmacokinetics of these two substances differ markedly. While the parent compound (allopurinol) has a half-life of only 1 to 3 hours, oxypurinol is eliminated much more slowly, with a half-life reaching 12 to 30 hours. This pharmacokinetic property ensures a prolonged therapeutic effect and maintains a stable inhibitory concentration of the active substance in the patient's blood throughout the day, preventing sharp fluctuations in uric acid levels.
Safety Profile and Adverse Effects of Allopurinol
Prescribing allopurinol requires strict clinical monitoring due to its specific safety profile. The most insidious and alarming complication during the first weeks of therapy is the paradoxical flare, presenting as a classic acute gout attack. The mechanism of this phenomenon is directly related to pharmacodynamics: as uric acid synthesis drops sharply, the concentration gradient shifts, causing urates to actively mobilize from tissue deposits back into the systemic circulation.
Allergic reactions are the leading adverse events, most frequently manifesting as skin rashes and dermatitis. Patients may also report gastrointestinal distress, particularly diarrhea. Central nervous system effects sometimes include persistent headaches and prominent daytime somnolence.
The drug has strict contraindications. It must not be prescribed during an acute gout attack (to avoid exacerbating urate mobilization), nor during pregnancy or breastfeeding. Additionally, severe renal or hepatic impairment serves as a major barrier to therapy.
Febuxostat: A Selective Alternative
In clinical situations where a patient is intolerant to allopurinol or requires a faster and more potent clinical response, febuxostat (Febuxostatum) is the drug of choice.
Its primary pharmacological advantage is high selectivity. Febuxostat acts as a strictly selective xanthine oxidase inhibitor. Unlike non-selective predecessors, it precisely targets the enzyme without disrupting complex metabolic pathways of other purines and pyrimidines, minimizing interference with normal cellular nucleic acid metabolism.
The clinical efficacy of febuxostat in severe hyperuricemia is very high. Complete normalization of serum uric acid levels (achieving target values) is typically achieved within 28 days of regular administration.
Adverse Reactions to Febuxostat
Despite its high selectivity and modern profile, febuxostat therapy requires careful patient monitoring. A specific adverse effect of this drug is its impact on the hepatobiliary system. Blood chemistry panels may reveal an asymptomatic elevation of liver transaminases, necessitating periodic laboratory checks.
Clinical manifestations involving the cardiovascular and central nervous systems are also possible. Patients occasionally report tachycardia and dizziness. Less frequent adverse effects include myositis—inflammatory skeletal muscle conditions accompanied by myalgia.